A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response-Dependent Survival of Quiescent Cancer Cells.
Veronica CalvoWei ZhengAnna Adam-ArtiguesKirk A StaschkeXin HuangJulie F CheungAna Rita NobreSho FujisawaDavid LiuMaria FumagalliDavid SurguladzeMichael E StokesAri NowacekMark J MulvihillEduardo F FariasJulio A Aguirre-GhisoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Our data identify PERK as a unique vulnerability in quiescent or slow-cycling ISRhigh DCCs. The use of PERK inhibitors may allow targeting of pre-existing or therapy-induced growth arrested "persister" cells that escape anti-proliferative therapies.
Keyphrases
- endoplasmic reticulum stress
- induced apoptosis
- endoplasmic reticulum
- squamous cell carcinoma
- small cell lung cancer
- high glucose
- cell cycle arrest
- electronic health record
- cancer therapy
- neural stem cells
- high intensity
- big data
- mesenchymal stem cells
- cell death
- endothelial cells
- bone marrow
- artificial intelligence
- cell therapy